Amneal launches Taytulla generic Taysofy
Taytulla and its generic equivalents had a market value of roughly $124.4 million in the 12 months ended June 2021, according to IQVIA.
Amneal is introducing norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules 1 mg/20 mcg, to be marketed as Taysofy.
The product is the generic of Abbvie's oral contraceptive brand Taytulla.
Taytulla and its generic equivalents had a market value of roughly $124.4 million in the 12 months ended June 2021, according to IQVIA.
Taysofye is packaged in cartons containing 5 unit-of-use 28-day blister packs. Each blister pack contains 24 days of active therapy and 4 days of ferrous fumarate supplements.